Fever, a common clinical symptom, often presents a diagnostic challenge due to its multifaceted etiology. An integrated approach to fever management can enhance patient outcomes, reduce unnecessary investigations, and streamline healthcare resources.
Fevers can be attributed to a broad spectrum of causes, ranging from infectious diseases to non-infectious conditions such as malignancies and autoimmune disorders. A thorough clinical evaluation, including history-taking and physical examination, can provide valuable clues to the underlying cause.
An algorithmic approach, guided by the patient's history, symptoms, and initial investigations, can aid in narrowing the differential diagnosis. This includes considering the duration of fever, associated symptoms, exposure history, and geographical location. Initial investigations typically include a complete blood count, inflammatory markers, and cultures if infection is suspected.
Management should be tailored to the underlying cause of fever. In cases of infection, appropriate antibiotics should be initiated promptly. For non-infectious causes, management of the underlying condition is paramount. Symptomatic treatment of fever with antipyretics should be considered, particularly in patients with discomfort or underlying cardiac conditions.
An integrated, multidisciplinary approach to fever management can optimize patient care. This involves collaboration between infectious disease specialists, rheumatologists, hematologists, and other relevant specialists, depending on the suspected etiology. Regular team discussions can facilitate a comprehensive and holistic approach to patient management.
Managing fever in clinical practice requires a nuanced and integrated approach, taking into account the multifaceted nature of its etiology. By adopting a systematic diagnostic approach, tailoring treatment to the underlying cause, and promoting multidisciplinary collaboration, healthcare professionals can enhance patient outcomes and optimize resource utilization in fever management.
1.
Prostate cancer detection with PET CT and PET MRI is comparable.
2.
Refractory Multiple Myeloma Responsive to Immunotherapy Plus Low-Dose Radiotherapy
3.
AI Breath Test IDs Cancers; More Grief for Prior Auth; Imatinib Discoverer Resigns
4.
In NSCLC, subcutaneous Lazertinib + Amivantamab Dosing Is Not Worse Than IV Dosing.
5.
Loncastuximab-Rituximab Boosts Response Rates in R/R Follicular Lymphoma
1.
Innovative Intraoperative Therapies in Neurosurgical Oncology: Advancing Precision and Outcomes
2.
Unlocking the Potential of Bicalutamide 50 mg: A Revolutionary New Treatment for Prostate Cancer
3.
Holistic Oncology: Advancing Survivorship, Nursing, and Innovative Cancer Care Models
4.
Emerging Chemo-Immunotherapy: New Agents and Mechanisms in Modern Oncology
5.
The Dangers of Supratherapeutic INR: The Need for Increased Awareness and Monitoring
1.
Asian Symposium on Advancement in Hematology and Oncology
2.
Asian Symposium on Advancement in Hematology and Oncology
3.
Asian Symposium on Advancement in Hematology and Oncology
4.
International Cancer Conference
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Thromboprophylaxis In Medical Settings
2.
EGFR Mutation Positive Non-Small Cell Lung Cancer- Case Discussion & Conclusion
3.
Recent Data Analysis for First-Line Treatment of ALK+ NSCLC
4.
Efficient Management of First line ALK-rearranged NSCLC
5.
Post Progression Approaches After First-line Third-Generaion ALK Inhibitors
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation